ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
Dow Jones
42.732,13
0,80%
Euro vs US Dollar
1,03115
0,00%
Bitcoin
97.621,88
-0,60%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Supernus Pharmaceuticals Inc (SUPN)

  7. Supernus Pharmaceuticals Inc (SUPN) News

SUPN

Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SUPN
DatumZeitQuelleÜberschriftSymbolFirma
30/12/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
30/12/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/12/202414h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/12/202414h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
20/12/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
16/12/202422h30GlobeNewswire Inc.Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in CanadaNASDAQ:SUPNSupernus Pharmaceuticals Inc
04/12/202422h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
03/12/202422h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/11/202423h00GlobeNewswire Inc.Supernus to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
14/11/202423h14Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SUPNSupernus Pharmaceuticals Inc
13/11/202422h30GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
12/11/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
12/11/202422h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/11/202423h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/11/202422h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/11/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/11/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
07/11/202422h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
07/11/202422h55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
07/11/202422h55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
04/11/202422h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SUPNSupernus Pharmaceuticals Inc
04/11/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
04/11/202422h05GlobeNewswire Inc.Supernus Announces Third Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
01/11/202421h35Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SUPNSupernus Pharmaceuticals Inc
31/10/202421h10GlobeNewswire Inc.Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
30/10/202421h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
21/10/202422h48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
21/10/202422h25GlobeNewswire Inc.Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
18/10/202412h09IH Market NewsiPhone 16 Sales in China Up 20%; Sobr Safe Jumps 108% Pre-Market; Netflix and Intuitive Surgical Beat EstimatesNASDAQ:SUPNSupernus Pharmaceuticals Inc
17/10/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SUPN

Kürzlich von Ihnen besucht

FX
EURUSD
Euro vs US Dollar
COIN
ADAUSD
Cardano
NASDAQ
AMZN
Amazon.com
AMEX
SPY
SPDR S&P 500
USOTC
RHHBY
Roche (QX)
USOTC
BASFY
BASF (QX)
NASDAQ
MSFT
Microsoft
TG
432
Arbor Metals
COIN
AVAXUSD
Avalanche
USOTC
ADDYY
Adidas (QX)
COIN
BTCUSD
Bitcoin
TG
CBK
Commerzbank
COIN
DOGEUSD
Dogecoin
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten